TD Cowen initiated coverage of Kiniksa (KNSA) with a Buy rating and $60 price target The firm says Kiniksa is at a “pivotal stage” as Arcalyst’s launch continues to ramp while KPL-387 could offer more favorable dosing. This could extend the franchise and significantly improve the company’s earnings, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA: